Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 7/20 | 0.52 |
| ▸ | GNAI3 | P08754 | 6/20 | 0.52 |
| ▸ | GNAI1 | P63096 | 6/20 | 0.52 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.42 |
| ▸ | GUSB | P08236 | 2/20 | 0.41 |
| ▸ | EBP | Q15125 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15921159 | 0.98 | GNAO1 (0.55) | GNAO1GNAI3GNAI1GUSBEBP | |
| SCHEMBL8429693 | 0.98 | GNAO1 (0.55) | GNAO1GNAI3GNAI1GUSBEBP | |
| SCHEMBL10354337 | 0.98 | GNAO1 (0.55) | GNAO1GNAI3GNAI1GUSBEBP | |
| SCHEMBL22222479 | 0.98 | GNAO1 (0.55) | GNAO1GNAI3GNAI1GUSBEBP | |
| SCHEMBL10584652 | 0.98 | GNAO1 (0.55) | GNAO1GNAI3GNAI1GUSBEBP | |
| SCHEMBL8431187 | 0.98 | GNAO1 (0.55) | GNAO1GNAI3GNAI1GUSBEBP | |
| SCHEMBL17526500 | 0.98 | GNAO1 (0.55) | GNAO1GNAI3GNAI1GUSBEBP | |
| SCHEMBL8283698 | 0.93 | GNAI3 (0.43) | GNAO1GNAI3GNAI1TLR8TLR7 | |
| SCHEMBL1920038 | 0.86 | GNAI3 (0.44) | GNAO1GNAI3GNAI1GUSBEBP | |
| SCHEMBL17526515 | 0.85 | GNAI3 (0.41) | GNAO1GNAI3GNAI1GUSBS1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3794650-B1 | ORGANIC SEMICONDUCTORS | RAYNERGY TEK INC (TW) | 2024-03-13 | — | — | EP | disclosed |
| US-20230374199-A1 | ORGANIC SEMICONDUCTORS | HOU JIANHUI (CN) | 2023-11-23 | — | — | US | disclosed |
| US-11603431-B2 | Organic semiconductors | Raynergy Tek Incorporation (TW) | 2023-03-14 | — | — | US | disclosed |
| EP-3411374-B9 | [1,5]NAPHTHYRIDINE COMPOUNDS AND POLYMERS AS SEMICONDUCTORS | RAYNERGY TEK INC (TW) | 2023-01-11 | — | — | EP | disclosed |
| EP-4008708-A1 | FULLERENE DERIVATIVES FOR ORGANIC SEMICONDUCTORS | Nano-C, Inc. (US) | 2022-06-08 | — | — | EP | disclosed |
| US-20220173321-A1 | ORGANIC SEMICONDUCTORS | RAYNERGY TEK INC (TW) | 2022-06-02 | — | — | US | disclosed |
| EP-3430016-B1 | ORGANIC SEMICONDUCTORS | RAYNERGY TEK INC (TW) | 2022-01-05 | — | — | EP | disclosed |
| EP-3157895-B1 | FULLERENE DERIVATIVES FOR ORGANIC SEMICONDUCTORS | NANO C INC (US) | 2021-12-29 | — | — | EP | disclosed |
| EP-3070756-B9 | SEMICONDUCTOR MIXTURES COMPRISING NANOPARTICLES | RAYNERGY TEK INC (TW) | 2021-11-03 | — | — | EP | disclosed |
| US-11130837-B2 | Organic semiconductors | Raynergy Tek Incorporation (TW) | 2021-09-28 | — | — | US | disclosed |
| WO-2005060949-A2 | SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF HOT FLASHES, IMPULSE CONTROL DISORDERS AND PERSONALITY CHANGE DUE TO A GENERAL MEDICAL CONDITION | ELI LILLY AND COMPANY (US) | 2005-07-07 | — | — | WO | disclosed |
| EP-1546123-A1 | BENZYL MORPHOLINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2005053663-A2 | NOREPINEPHRINE REUPTAKE INHIBITORS USEFUL FOR TREATMENT OF COGNITIVE FAILURE | ELI LILLY AND COMPANY (US) | 2005-06-16 | — | — | WO | disclosed |
| EP-1534291-A2 | 2-(PHENOXYMETHYL)- AND 2-(PHENYLTHIOMETHYL)- MORPHOLINE DERIVATIVES FOR USE AS SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-06-01 | — | — | EP | disclosed |
| WO-2005020976-A2 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005020975-A2 | TREATMENT OF LEARNING DISABILITIES AND MOTOR SKILLS DISORDER WITH NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005021095-A2 | TREATMENT OF STUTTERING AND OTHER COMMUNICATION DISORDERS WITH NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2004103356-A2 | TREATMENT OF EMOTIONAL DYSREGULATION | ELI LILLY AND COMPANY (US) | 2004-12-02 | — | — | WO | disclosed |
| WO-2004017977-A2 | 2- (PHENOXYMETHYL)- AND 2- (PHENYLTHIOMETHYL)-MORPHOLINE DERIVATIVES FOR USE AS SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2004-03-04 | — | — | WO | disclosed |
| WO-2004018440-A1 | BENZYL MORPHOLINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11603431-B2 | Organic semiconductors | OCIAD2, OCIAD1, PPOX | GNAO1 1294/4885GNAI3 2462/4885GNAI1 2008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.